Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus, GLP-1 agonist
The most effective weight loss medication in history — FDA-approved GLP-1 agonist with transformative results.
Molecular structure image coming soon
FDA-approved prescription medication. Available through licensed prescribers and compounding pharmacies. Risk of thyroid C-cell tumors in animal studies. Not for use in patients with personal/family history of MTC.
Overview
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes (Ozempic) and subsequently approved at higher doses for chronic weight management (Wegovy). It has become one of the most prescribed medications globally, demonstrating unprecedented weight loss results in clinical trials — up to 15–17% body weight reduction. Available through compounding pharmacies during FDA drug shortages.
Mechanism of Action
Semaglutide mimics glucagon-like peptide-1 (GLP-1), a gut hormone released after eating. It slows gastric emptying, reduces appetite via central nervous system GLP-1 receptors, enhances insulin secretion, and suppresses glucagon. The net effect is profound reduction in caloric intake and improved metabolic function.
Use Cases
- ✓Chronic weight management (FDA-approved, Wegovy)
- ✓Type 2 diabetes management (FDA-approved, Ozempic)
- ✓Cardiovascular risk reduction (FDA-approved)
- ✓NAFLD/NASH treatment (emerging)
- ✓Metabolic syndrome
Research Summary
The STEP trial series demonstrated 15–17% weight reduction vs 2–3% for placebo. The SELECT trial showed 20% reduction in MACE (major adverse cardiovascular events). Semaglutide is one of the most evidence-backed weight loss interventions ever studied, with dozens of Phase III and IV trials completed.
Typical Dosing
Wegovy: 0.25 mg/week titrating to 2.4 mg/week. Ozempic: 0.5–2 mg/week. Compounded semaglutide: varies by prescriber protocol.
Administration
Prescription Only
FDA-approved prescription medication. Available through licensed prescribers and compounding pharmacies. Risk of thyroid C-cell tumors in animal studies. Not for use in patients with personal/family history of MTC.
